An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial
- PMID: 26529126
- DOI: 10.1002/hep.28332
An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial
Abstract
Early diagnosis and appropriate treatment of infections in cirrhosis are crucial because of their high morbidity and mortality. Multidrug-resistant (MDR) infections are on the increase in health care settings. Health-care-associated (HCA) infections are still frequently treated as community-acquired with a detrimental effect on survival. We aimed to prospectively evaluate in a randomized trial the effectiveness of a broad spectrum antibiotic treatment in patients with cirrhosis with HCA infections. Consecutive patients with cirrhosis hospitalized with HCA infections were enrolled. After culture sampling, patients were promptly randomized to receive a standard or a broad spectrum antibiotic treatment (NCT01820026). The primary endpoint was in-hospital mortality. Efficacy, side effects, and the length of hospitalization were considered. Treatment failure was followed by a change in antibiotic therapy. Ninety-six patients were randomized and 94 were included. The two groups were similar for demographic, clinical, and microbiological characteristics. The prevalence of MDR pathogens was 40% in the standard versus 46% in the broad spectrum group. In-hospital mortality showed a substantial reduction in the broad spectrum versus standard group (6% vs. 25%; P = 0.01). In a post-hoc analysis, reduction of mortality was more evident in patients with sepsis. The broad spectrum showed a lower rate of treatment failure than the standard therapy (18% vs. 51%; P = 0.001). Length of hospitalization was shorter in the broad spectrum (12.3 ± 7 days) versus standard group (18 ± 15 days; P = 0.03). Five patients in each group developed a second infection during hospitalization with a similar prevalence of MDR (50% broad spectrum vs. 60% standard).
Conclusions: A broad spectrum antibiotic therapy as empirical treatment in HCA infections improves survival in cirrhosis. This treatment was significantly effective, safe, and cost saving.
© 2015 by the American Association for the Study of Liver Diseases.
Similar articles
-
The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey.PLoS One. 2015 May 21;10(5):e0127448. doi: 10.1371/journal.pone.0127448. eCollection 2015. PLoS One. 2015. PMID: 25996499 Free PMC article.
-
A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients.Clinicoecon Outcomes Res. 2017 Jun 29;9:385-390. doi: 10.2147/CEOR.S130725. eCollection 2017. Clinicoecon Outcomes Res. 2017. PMID: 28721080 Free PMC article.
-
A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy.Clin Infect Dis. 2013 Nov;57(10):1373-83. doi: 10.1093/cid/cit571. Epub 2013 Sep 2. Clin Infect Dis. 2013. PMID: 23999080
-
Current guidelines for the treatment of severe pneumonia and sepsis.Chemotherapy. 2005 Aug;51(5):227-33. doi: 10.1159/000087452. Chemotherapy. 2005. PMID: 16103664 Review.
-
Antimicrobial de-escalation strategies in hospitalized patients with pneumonia, intra-abdominal infections, and bacteremia.J Hosp Med. 2012;7 Suppl 1:S13-21. doi: 10.1002/jhm.983. J Hosp Med. 2012. PMID: 23737333 Review.
Cited by
-
Antibiotic treatment in cirrhotic patients.World J Clin Cases. 2023 Dec 16;11(35):8242-8246. doi: 10.12998/wjcc.v11.i35.8242. World J Clin Cases. 2023. PMID: 38130612 Free PMC article.
-
Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections in Patients With Liver Cirrhosis.J Clin Exp Hepatol. 2022 Sep-Oct;12(5):1293-1300. doi: 10.1016/j.jceh.2022.04.016. Epub 2022 Apr 21. J Clin Exp Hepatol. 2022. PMID: 36157152 Free PMC article.
-
Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis.Am J Gastroenterol. 2019 Jul;114(7):1091-1100. doi: 10.14309/ajg.0000000000000280. Am J Gastroenterol. 2019. PMID: 31180922 Free PMC article.
-
Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure.Medicine (Baltimore). 2017 Sep;96(37):e8057. doi: 10.1097/MD.0000000000008057. Medicine (Baltimore). 2017. PMID: 28906399 Free PMC article.
-
The multi-drug resistant organisms infections decrease during the antimicrobial stewardship era in cirrhotic patients: An Italian cohort study.PLoS One. 2023 Feb 16;18(2):e0281813. doi: 10.1371/journal.pone.0281813. eCollection 2023. PLoS One. 2023. PMID: 36795664 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical